Company / SG&A per Share
Travere Therapeutics, Inc. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$3.86
FY2025
5-year range
$2.47 / $4.13
FY2021-FY2025
Trend
+10.0%
vs FY2024
Sector context
#47 of 210
Health Care
What the data says
Travere Therapeutics, Inc.'s sg&a per share of $3.86 is higher than 78% of companies in the Health Care sector (FY2025). SG&A per Share has fluctuated over the past 10 years, ranging from $1.64 in FY2016 to $4.13 in FY2023.
Based on SEC 10-K filings.
3.86 in FY2025 with a 5-year CAGR of +9.9%. Top quartile in the Health Care sector.
Improved from $4.13 to $3.86 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +6.9%
- 5-Year CAGR
- +9.9%
- 10-Year CAGR
- -
Sector benchmark
-90.5% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share increased 10.0% year-over-year.
- Ranks #47 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2023.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.86 | +10.0% |
| FY2024 | $3.50 | -15.2% |
| FY2023 | $4.13 | +30.7% |
| FY2022 | $3.16 | +28.1% |
| FY2021 | $2.47 | +2.6% |
| FY2020 | $2.41 | -1.7% |
| FY2019 | $2.45 | +4.8% |
| FY2018 | $2.34 | +11.3% |
| FY2017 | $2.10 | +28.3% |
| FY2016 | $1.64 | -46.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026